1 Cost-effectiveness of vildagliptin for people with Type 2 Diabetes Mellitus in Brazil ; findings and implications

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies

  2017cited by this paper
• Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.

  2017cited by this paper
• Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.

  2017cited by this paper
• Towards better patient care: drugs to avoid in 2016.

  2016cited by this paper
• Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness

  2016cited by this paper
• Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes

  2016cited by this paper
• Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia

  2016cited by this paper
• Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care

  2016cited by this paper
• Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications

  2016cited by this paper
• Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes

  2016cited by this paper
• Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.

  2016cited by this paper
• Metformin is backed as first line therapy for type 2 diabetes

  2016cited by this paper
• Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

  2015cited by this paper
• Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness

  2015cited by this paper
• Medication adherence in type 2 diabetes patients: study of patients in Alimosho General Hospital, Igando, Lagos, Nigeria.

  2015cited by this paper
• Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

  2015cited by this paper
• Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes

  2015cited by this paper
• Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients

  2015cited by this paper
• Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

  2015cited by this paper
• Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective

  2014cited by this paper
• Healthcare Costs of the Combination of Metformin/Dipeptidyl Peptidase-4 Inhibitors Compared with Metformin/Other Oral Antidiabetes Agents in Patients with Type 2 Diabetes and Metabolic Syndrome

  2014cited by this paper
• Insulin Glargine in a Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review

  2014cited by this paper
• Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.

  2014cited by this paper
• Value in Pharmaceutical Pricing

  2013cited by this paper
• UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82

  2013cited by this paper
• Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)

  2013cited by this paper
• A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

  2013cited by this paper
• Adherence to Therapies in Patients with Type 2 Diabetes

  2013cited by this paper
• NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium

  2012cited by this paper
• Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.

  2012cited by this paper
• Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet]

  2011cited by this paper
• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  2010cited by this paper
• Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

  2009cited by this paper
• A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study

  2009cited by this paper
• Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

  2009cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• Decision modelling for health economic evaluation

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

  2007cited by this paper
• Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.

  2006cited by this paper
• Markov Models in Medical Decision Making : A Practical Guide

  2006cited by this paper
• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  2005cited by this paper
• Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms.

  2003cited by this paper
• Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial

  year unknowncited by this paper

• A Structured Educational Intervention for Enhancing Self- Management and Readiness of Diabetic Adolescent for the Health-Care Transition

  2019influential citation